Gene Editing Companies Landscape

Gene editing has emerged as one of the most transformative technologies in biotech and pharma, with applications spanning therapeutics, diagnostics, research tools, and biomanufacturing. As CRISPR-based technologies, base editing, and prime editing advance, the industry has witnessed rapid commercialization, particularly with the approval of Casgevy and Lyfgenia in December 2023. This report provides an in-depth look at the global gene editing landscape, analyzing company distribution, industry segmentation, investment trends, and clinical developments shaping the sector.

The data presented in this report utilized our biopharmIQ platform, which tracks bio/pharma companies, including gene editing companies globally (academic/hospital/research centers were excluded from this analysis). While we strive for accuracy for our entire database, and completeness for biopharma companies, there is a probability that some companies working in gene editing may not have been captured in this dataset. Moreover, our platform undergoes daily updates to add more companies, so the numbers may change. The data collection cut-off for this report is February 28, 2025. Check out our free list of 300+ gene editing companies by clicking on the figure 1 image below.

Figure 1. Gene editing companies landscape.

Global Landscape of Gene Editing Companies

The gene editing sector continues to expand globally, with 332 identified companies across 23 countries. The United States remains the dominant hub with 217 companies, followed by China (30), the United Kingdom (16), Germany (13), and France (8). While North America leads in company count, Europe and Asia-Pacific are strengthening their presence in gene editing innovation.

Global Distribution of Gene Editing Companies

• United States (217 companies) – Home to a vast majority of gene editing companies, particularly in biotech-heavy regions such as California and Massachusetts.

• China (30 companies) – A rapidly growing hub for gene editing, with companies focusing on therapeutic applications and CRISPR-based technologies.

• United Kingdom (16 companies) – A strong presence in genome editing tools and therapeutics, with notable companies like Cellectis and Oxford Genetics.

• Germany (13 companies) – Focused on gene editing for regenerative medicine and cell therapies.

• France (8 companies), Netherlands (7), Switzerland (5), and Ireland (5) – European countries with a growing presence in CRISPR technologies and gene-edited therapies.

Other key contributors include South Korea, Singapore, Japan, and Canada, each with at least two or more gene editing companies making advances in the field.

Figure 2. Gene editing companies by country.

United States Overview: State-by-State Distribution

Within the 217 U.S.-based gene editing companies, California and Massachusetts remain the largest biotech hubs, accounting for over 60% of the total. Other states with notable activity include New York, Pennsylvania, North Carolina, Maryland, and Texas, all supporting growing biotech clusters that contribute to gene editing research and development.

Top U.S. States for Gene Editing Companies

• California (68 companies) – The largest biotech hub in the U.S., home to key players such as Inscripta, Synthego, and Mammoth Biosciences, driving CRISPR research and commercialization.

• Massachusetts (63 companies) – A powerhouse in gene editing, home to Editas Medicine, Beam Therapeutics, and Intellia Therapeutics, supported by a strong academic ecosystem from Harvard and MIT.

• New York (15 companies) – Hosts growing startups like Century Therapeutics, benefiting from New York’s major research institutions and hospital networks.

• Pennsylvania (10 companies), North Carolina (7), Maryland (7), and Texas (6) – Emerging biotech hubs with strong investment in gene editing innovation.

  
  

Other Notable States: Washington (5), New Jersey (5), Florida (4), Delaware (4), Wisconsin (3), Missouri (3), Virginia (2), Ohio (2), Kentucky (2), Iowa (2), Illinois (2), Colorado (2), North Dakota (1), Minnesota (1), Michigan (1), Kansas (1), Indiana (1) each contribute to the expanding gene editing ecosystem.

Figure 3. US-based gene editing companies by state.

Industry Segmentation: Therapeutic, Contract Research & Manufacturing, Vendor, and Diagnostics

Gene editing companies operate across four primary categories, with some participating in multiple segments. For the purpose of this report, companies have been categorized by their primary business focus.

• Therapeutic Developers (205 companies) – The largest segment, focused on gene-editing-based treatments for oncology, rare diseases, and regenerative medicine. Key players include Beam Therapeutics, CRISPR Therapeutics, Editas Medicine, and Prime Medicine.

• Vendors (104 companies) – Companies providing gene editing reagents, tools, and services for research and clinical applications. Leading vendors include Synthego, Integrated DNA Technologies (IDT), and GenScript.

• Contract Research & Manufacturing (19 companies) – Supporting GMP manufacturing, preclinical research, and quality control. Key players include Aldevron, ElevateBio, and Oxford Genetics.

• Diagnostics (4 companies) – Developing CRISPR-based diagnostic tools for genetic and infectious diseases. Notable companies include Sherlock Biosciences, Precede Biosciences, Avellino AI, and DNAiTECH.

Figure 4. Gene editing companies by company type.

Conclusion

The gene editing industry continues to expand, with 332 identified companies, primarily concentrated in the United States (217 companies), followed by China and the UK. The sector spans therapeutics, contract research & manufacturing, vendors, and diagnostics, with therapeutic applications leading growth.

Beyond therapeutics, contract research and manufacturing organizations support scalability, while vendors supply critical gene editing tools for research and clinical applications. As trials progress, regulatory decisions and emerging technologies will define the future trajectory of gene editing in bio/pharma. This robust and expanding ecosystem of companies that develop and utilize gene editing technologies provides a tremendous and growing opportunity for sales/marketing and business development professionals from companies whose products and services benefit gene editing companies. 

Our BiopharmIQ systems continue to capture bio/pharma gene editing companies. We are excited to see how this sector continues to grow in 2025. Join our email list to receive bio/pharma corporate and clinical trial insights in your inbox.

Get the full length white paper report here.

📅 Book your demo today or if have questions, send us an email at marketing@biopharmIQ.com.

***

Article History:

Maryam D., Rex F., Danilo G., Manny V. (Published: 3 April 2025)

Not legal, investing, or tax advice.